Catalyst Event

Hansoh Pharmaceutical Group Company Limited (3692) · Other

From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)

4/29/2026, 12:00:00 AM

OtherSentiment: Positive

The B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 was granted Breakthrough Therapy Designation by China's NMPA for the treatment of advanced castration-resistant prostate cancer.

Korean Translation

B7-H3 표적 항체-약물 접합체(ADC) HS-20093이 진행성 거세 저항성 전립선암 치료제로 중국 국가약품감독관리국(NMPA)으로부터 혁신치료제 지정을 받음.

Related Recent Events

View Full Timeline